It is currently estimated that in approximately 16% of RUNX1-mutated AML patients the identified RUNX1 variant is indeed of germline origin — higher percentages were reported but germline pathogenicity was not established for all variants (15, 29). This evidence concerns the gene RUNX1 and acute myeloid leukemia.